Zymeworks Balance Sheet Health
Financial Health criteria checks 6/6
Zymeworks has a total shareholder equity of $367.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $487.2M and $120.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$297.20m |
| Equity | US$366.98m |
| Total liabilities | US$120.17m |
| Total assets | US$487.15m |
Recent financial health updates
Recent updates
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking
Nov 08
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
Nov 04Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Nov 03Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook
Nov 01Zymeworks Approaching A Moment Of Truth With Zanidatamab
Sep 27Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week
Aug 07Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up
Jul 26Zymeworks: A Somewhat Complicated Story
Jul 09Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans
Jun 12Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business
May 03Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Financial Position Analysis
Short Term Liabilities: ZYME's short term assets ($343.8M) exceed its short term liabilities ($83.9M).
Long Term Liabilities: ZYME's short term assets ($343.8M) exceed its long term liabilities ($36.3M).
Debt to Equity History and Analysis
Debt Level: ZYME is debt free.
Reducing Debt: ZYME had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZYME has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ZYME has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 2.9% each year